|Videos|December 13, 2022
A Model That Is Built to “Win”
Cutting the amount of Monthly Enhanced Oncology Services payments and limiting qualifying tumor types will curtail revenue to practices. But after the financial results in the Oncology Care Model, that's by design.
Advertisement
Episodes in this series
Panelists discuss the financial fallout from the design of the Enhancing Oncology Model (EOM), which responds to the reports that found the Oncology Care Model succeeded in delivering better care but didn't save enough Medicare enough money in its early years, at least not in practices that were less proficient in operating the model. Kashyap Patel, MD, suggests other payment model programs that could work in tandem with the EOM.
Advertisement
Related to this article
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5